KalVista Pharmaceuticals
Financial ratios & Valuation

Forward Multiples (2026 – 2028)

202620272028
Price/Earnings ratio
-25.7471.168.40
Price/Sales ratio
2.641.891.36
Earnings per Share (EPS)
$-0.49$0.18$1.52

Historical Multiples (2014 – 2024)

2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 TTM Median
Valuation Ratios
Price/Earnings ratio
-12.60-4.27-3.78-6.28-16.66-6.65-10.71-4.54-3.30-3.29-2.64-16.66
Price/Sales ratio
50.4922.9146.8211.8221.5015.2537.57N/AN/AN/AN/A15.25
Price/Book Value ratio
-2.062.272.243.643.582.311.851.681.532.021.292.31
Price/Cash Flow ratio
-14.30-3.71-2.969.40-9.53-4.32-15.80-3.98-3.28-4.67-3.01-9.53
Price/Free Cash Flow ratio
-14.03-3.71-2.9510.87-9.26-4.29-15.76-3.94-3.23-4.65-2.97-9.26
Price/Earnings Growth ratio
0.590.060.180.301.69-0.35-0.25-0.220.77-0.110.050.05
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
99.54%99.31%99.15%99.78%99.78%99.68%94.87%N/AN/AN/AN/A99.68%
Operating Profit Margin
-448.39%-711.72%-1485.30%-222.83%-184.90%-319.40%-456.44%N/AN/AN/AN/A-184.90%
Pretax Profit Margin
-400.55%-536.14%-1236.90%-188.28%-128.30%-230.41%-364.41%N/AN/AN/AN/A-128.30%
Net Profit Margin
-400.55%-536.14%-1236.90%-188.28%-129.07%-229.44%-350.62%N/AN/AN/AN/A-129.07%
Effective Tax Rate
11.94%47.27%27.45%8.38%-0.59%0.42%3.78%16.79%19.43%6.25%N/A-0.59%
Return on Assets
-108.75%-46.21%-54.16%-25.74%-17.62%-31.46%-16.35%-33.60%-40.85%-53.79%-44.58%-31.46%
Return On Equity
16.35%-53.20%-59.38%-57.99%-21.51%-34.76%-17.29%-37.01%-46.48%-61.30%-53.52%-34.76%
Return on Capital Employed
1801.55%-70.62%-71.30%-49.00%-29.79%-47.79%-22.08%-50.23%-65.92%-66.06%-55.22%-47.79%
Liquidity Ratios
Current Ratio
N/A7.5911.342.556.4011.4827.03N/AN/AN/A16.556.40
Quick Ratio
0.647.5911.342.556.4011.4827.0316.4911.469.8915.886.40
Cash ratio
0.546.6910.252.191.772.045.172.653.741.397.321.77
Days of Sales Outstanding
N/A60.91618.12297.16256.09475.36299.65N/AN/AN/AN/A475.36
Days of Inventory outstanding
-10.37N/AN/AN/AN/AN/AN/A1.33KN/AN/AN/AN/A
Operating Cycle
-10.3760.91618.12297.16256.09475.36299.65N/AN/AN/AN/A475.36
Days of Payables Outstanding
45.11K25.09K33.22K28.68K29.80K15.22K1.11K1.78K2.19K38.57N/A15.22K
Cash Conversion Cycle
-45.12K-25.03K-32.60K-28.38K-29.55K-14.75K-811.04N/AN/AN/AN/A-29.55K
Debt Ratios
Debt Ratio
0.98N/AN/AN/AN/AN/AN/AN/AN/AN/A0.09N/A
Debt Equity Ratio
-0.14N/AN/AN/AN/AN/AN/AN/AN/AN/A0.10N/A
Long-term Debt to Capitalization
-0.05N/AN/AN/AN/AN/AN/AN/AN/AN/A0.03N/A
Total Debt to Capitalization
-0.17N/AN/AN/AN/AN/AN/AN/AN/AN/A0.04N/A
Interest Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A-62.65N/A
Cash Flow to Debt Ratio
-0.96N/AN/AN/AN/AN/AN/AN/AN/AN/A-9.36N/A
Company Equity Multiplier
-0.151.151.092.251.221.101.051.101.131.131.101.10
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
-3.52-6.16-15.771.25-2.25-3.53-2.37N/AN/AN/AN/A-2.25
Free Cash Flow / Operating Cash Flow Ratio
1.011.001.000.861.021.001.001.011.011.001.011.01
Cash Flow Coverage Ratio
-0.96N/AN/AN/AN/AN/AN/AN/AN/AN/A-9.36N/A
Short Term Coverage Ratio
-1.43N/AN/AN/AN/AN/AN/AN/AN/AN/A-75.13N/A
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A